Latest
By Philip Joens / Wednesday, October 28th, 2015 / Central Coast Health Watch, Latest news, Top Stories, Tri-County Public Companies / Comments Off on Amgen’s third quarter earnings beat Wall Street expectations
Thousand Oaks biotech giant Amgen blew Wall Street away when it released third quarter earnings on Oct. 28. Amgen beat analyst revenue estimates by posting revenues of $5.72 billion, compared to the $5.23 billion analysts expected. That’s up from about $5 billion during last year’s third quarter. Net income increased to $1.86 billion during the Read More →
Read More →
Latest
By Philip Joens / Wednesday, October 28th, 2015 / Central Coast Health Watch, Latest news, Top Stories, Tri-County Public Companies / Comments Off on Sientra CEO ducks questions about company’s future
Sientra CEO Hani Zeini said in a conference call on Oct. 28 that he will not speculate about the company’s future. Zeini dodged questions better than a Brooklyn Dodger dodges street cars during the call with investors, analysts and reporters to update all parties about implants contaminated by Sientra’s manufacturer. Sientra shares nosedived on Sept. Read More →
Read More →
Latest
By Staff Report / Tuesday, October 27th, 2015 / Central Coast Health Watch, Latest news, Top Stories, Tri-County Public Companies / Comments Off on FDA OKs Amgen skin cancer drug Imlygic
The U.S. Food and Drug Administration on Oct. 27 approved Amgen’s cancer immunotherapy drug Imlygic for use in patients with the most deadly types of skin cancer. Imlygic, which is the first immunotherapy like this to gain approval for use in the U.S., is a genetically modified herpes virus that is designed to replicate itself Read More →
Read More →
Latest
By Philip Joens / Friday, October 16th, 2015 / Central Coast Health Watch, Latest news, Top Stories, Tri-County Public Companies / Comments Off on Breast implant manufacturer Sientra’s stock price hits all-time low
Shares of Sientra hit a new all-time low on Oct. 16 when the stock fell another six cents on the day and closed at $5.77 per share. For the Goleta-based breast implant manufacturer, it marks another low in a saga that’s starting to turn ugly. Shares of Sientra initially plummeted from $20.58 per share to Read More →
Read More →
